1. Targeted Therapy Management in NSCLC Patients Using Cytology: Experience from a Tertiary Care Cancer Center.
- Author
-
Veldore VH, Patil S, Prabhudesai S, Satheesh CT, Shashidhara HP, Krishnamoorthy N, Hazarika D, Tejaswi R, Prabhudev A, Naik R, Rao RM, and Kumar BS
- Subjects
- Biopsy, Fine-Needle, Carcinoma, Non-Small-Cell Lung drug therapy, Exons, Female, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms drug therapy, Male, Molecular Targeted Therapy, Tertiary Healthcare, Carcinoma, Non-Small-Cell Lung genetics, DNA Mutational Analysis methods, ErbB Receptors genetics, Lung Neoplasms genetics, Mutation
- Abstract
Background: Although biopsy is the gold standard for diagnosis, cytological material has often been used to assist in making a pathologic diagnosis as well as for molecular testing in certain cancers such as in the lung, cervix, and head/neck., Objective: Our objective is to share experience from our institution in the use of cytological material in screening for epidermal growth factor receptor (EGFR) mutations in a subset of patients with non-small cell lung cancer (NSCLC)., Methods: Fine needle aspirates, pleural effusion, cell blocks of 223 NSCLC patients, where cytology suggested malignancy were screened for EGFR mutation in exons 18-21 using Scorpion(®) ARMS real-time polymerase chain reaction (PCR) technology., Results: Overall, EGFR mutation was seen in 43.5 % of study samples. Deletions were highest in exon 19 (27.2 %), followed by exon 21 (15.5 %), exon 18 (5.3 %), and exon 20 (1.9 %). Chi-squared analysis revealed a significant correlation for mutation status in women compared with men (χ (2) = 5.88, p = 0.02), with exon 19 mutation predominating (χ (2) = 5.66, p = 0.02)., Conclusion: Our results demonstrate the successful use of cytology material for molecular testing in a subset of NSCLC patients to direct their treatment.
- Published
- 2016
- Full Text
- View/download PDF